IP Library Granted Patent US 12,168,701
Granted Patent B2
US 12,168,701 · App. 18/384,643 · Granted Dec 17, 2024

Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Inventors: Steven Pfeiffer (West Hollywood, CA); Dustin McMinn (West Hollywood, CA); Gabor Benkovics (Budapest, HU)
Assignee: BEREN THERAPEUTICS P.B.C.
C08B37/0012
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,168,701
App. No.
18/384,643
Granted
Dec 17, 2024
Kind
B2
Abstract

The present disclosure relates to compositions comprising mixtures of hydroxypropyl-β-cyclodextrin, wherein the compositions may be isomerically purified. The disclosure also relates to methods of isomerically purifying a mixture of hydroxypropyl-β-cyclodextrins.

Claims (13)

1. A composition comprising a mixture of isomerically-purified hydroxypropyl β-cyclodextrin molecules comprising: β-cyclodextrin substituted with seven hydroxypropyl groups (“DS-7”); and wherein the composition comprises less than 1% β-cyclodextrin substituted with six hydroxypropyl groups (“DS-6”) wherein the total amount of impurities are measured to be less than or equal to 0.05% by HPLC.

2. The composition of claim 1 , wherein the composition further comprises less than 1% β-cyclodextrin substituted with five hydroxypropyl groups (“DS-5”).

3. The composition of claim 1 , wherein the composition further comprises less than 1% β-cyclodextrin substituted with four hydroxypropyl groups (“DS-4”).

4. The composition of claim 1 , wherein the composition further comprises less than 1% β-cyclodextrin substituted with three hydroxypropyl groups (“DS-3”).

5. The composition of claim 1 , wherein the mixture further comprises less than 0.05% unsubstituted beta-cyclodextrin (“DS-0”) and less than 0.05% β-cyclodextrin substituted with one hydroxypropyl group (“DS-1”).

6. The composition of claim 1 , wherein the composition has a mean retention time of about 15.4 minutes.

7. The composition of claim 1 , wherein the osmolality of the composition is about 635-695 mOs/kg; and/or wherein the true density of the composition is about 1.096-1.098 g/cm 3 .

8. The composition of claim 1 , wherein the composition further comprises no more than 10 ppb of propylene glycol as measured by HPLC.

9. The composition of claim 1 , wherein the composition further comprises no more than 10 ppb propylene glycol as measured by gas chromatography.

10. The composition of claim 1 , wherein the composition further comprises no more than 10 ppb propylene glycol as measured by PG/EG-ratio of propylene glycol to ethylene glycol.

11. The composition of claim 1 , wherein the composition comprises no more than 1 ppm propylene oxide.

12. The composition of claim 1 , wherein the composition comprises between 0 and 10 ppm chloride.

13. The composition of claim 1 , wherein the composition has a conductivity between 0 and 8 μS/cm.

Assignments (2)
SECURITY INTEREST Recorded Oct 8, 2025
From: BEREN THERAPEUTICS P.B.C.; MANDOS LLC
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 073056/0214 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2024
From: PFEIFFER, STEVEN; MCMINN, DUSTIN; BENKOVICS, GABOR
To: BEREN THERAPEUTICS P.B.C.
Reel/Frame 066443/0497 →